PDF icon Download PDF
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(04): 301-305
DOI: 10.1055/s-0043-1774328
Original Article

Expected Usefulness of Fourth Dose of COVID-19 Vaccine for Patients with Underlying Solid Tumor who Previously Received the Primary Heterologous COVID-19 Vaccine

Sora Yasri
1   KM Center, Bangkok Thailand
,
Viroj Wiwanitkit
2   Department of Biological Science, Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria
3   Department of Community Medicine, Dr. DY Patil Medical College - Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra, India
› Author Affiliations
Funding None.
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Coronavirus disease 2019 (COVID-19) immunization frequently requires two standard doses. Due to the likelihood that the population may lose immunity after receiving a standard mass vaccination and the potential for the introduction of a new strain, several scientists are currently advocating the use of a booster dosage of the vaccine.

The authors of this retrospective study used a clinical model for immune response prediction to forecast how solid cancer patients will respond to the fourth dosage of the COVID-19 immunization. In the case of homologous primary backgrounds, the prospective rates of extension of protective efficacy for using viral vector and messenger ribonucleic acid (mRNA) COVID-19 vaccines for vaccinees with underlying solid tumor are equal to 11.5 and 16.5%, respectively. In the event of heterologous primary backgrounds, the prospective rates of extension of protective efficacy for using viral vector and mRNA COVID-19 vaccines are equal to 2.2 and 7.2%, respectively, for patients with underlying solid cancer. In conclusion, the fourth dose of the COVID-19 vaccine regimen had an effect on the immunogenicity of vaccine recipients with underlying malignancy.

Keywords

COVID-19 - dose - fourth - vaccine - cancer

Patient Consent

This study is a clinical mathematical model study and does not directly deal with patients, and therefore, ethical approval is not applicable, and the consent form is also not applicable.




Publication History

Article published online:
30 January 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India